现在,普遍存在的肥胖和糖尿病对取得的这些成绩构成了威胁,而且白人患者和少数民族――尤其是非洲裔美国人――在从有效的治疗策略中获益的程度上存在很大的差异。
There have been few new transformative cardiovascular treatments since the mid-1980s to early 1990s, when a stream of large-scale trials of new agents ranging from clot-busters to treat heart attacks to the mega class of statins electrified the cardiology field with evidence of significant improvements in survival from the disease. One reason: Some of those remedies have proven tough to beat with new treatments.
从1980年代中期到1990年代初期,治疗心血管疾病的方法就没有多少新的改变(自那以后,对治疗心脏病发作的溶血剂和大量降低胆固醇的他汀类药物等新药进行的一系列大规模试验证明患心脏病的生存几率可以大大提高,这让心脏病学界兴奋不已)。其中一个原因是:那些疗法中有些被证明很难被新的治疗手段所超越。
What's more, use of the current menu of medicines for reducing heart risk remains an imprecise art. Besides blood pressure drugs, cholesterol-lowering statins also are widely prescribed. Drug-trial statistics show that to prevent a single first heart attack in otherwise healthy patients can require prescribing a statin to scores of patients, but no one knows for sure who actually benefits and who doesn't.
【心脏病治疗的最新前沿消息】相关文章:
★ 又到一年飞絮季 北京绘“杨柳地图” 力争到2020年改善
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15